322 related articles for article (PubMed ID: 25766118)
1. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer.
Minion LE; Bai J; Monk BJ; Robin Keller L; Ramez EN; Forde GK; Chan JK; Tewari KS
Gynecol Oncol; 2015 Jun; 137(3):490-6. PubMed ID: 25766118
[TBL] [Abstract][Full Text] [Related]
2. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer.
Montero AJ; Avancha K; Glück S; Lopes G
Breast Cancer Res Treat; 2012 Apr; 132(2):747-51. PubMed ID: 22200867
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer.
Mehta DA; Hay JW
Gynecol Oncol; 2014 Mar; 132(3):677-83. PubMed ID: 24463160
[TBL] [Abstract][Full Text] [Related]
4. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer.
Goulart B; Ramsey S
Value Health; 2011; 14(6):836-45. PubMed ID: 21914503
[TBL] [Abstract][Full Text] [Related]
5. Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada.
Hedden L; Kennecke H; Villa D; Johnston K; Speers C; Kovacic L; Renouf DJ; Peacock S
Eur J Cancer; 2012 Sep; 48(13):1969-76. PubMed ID: 22325838
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective?
Phippen NT; Leath CA; Havrilesky LJ; Barnett JC
Gynecol Oncol; 2015 Jan; 136(1):43-7. PubMed ID: 25448456
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
[TBL] [Abstract][Full Text] [Related]
8. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model.
Patel JJ; Mendes MA; Bounthavong M; Christopher ML; Boggie D; Morreale AP
J Eval Clin Pract; 2012 Apr; 18(2):247-55. PubMed ID: 20846318
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
Shiroiwa T; Fukuda T; Tsutani K
Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
[TBL] [Abstract][Full Text] [Related]
11. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis.
Cohn DE; Kim KH; Resnick KE; O'Malley DM; Straughn JM
J Clin Oncol; 2011 Apr; 29(10):1247-51. PubMed ID: 21383297
[TBL] [Abstract][Full Text] [Related]
12. Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC).
Lawrence D; Maschio M; Leahy KJ; Yunger S; Easaw JC; Weinstein MC
J Med Econ; 2013 Dec; 16(12):1387-98. PubMed ID: 24102083
[TBL] [Abstract][Full Text] [Related]
13. Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
Kovic B; Xie F
J Clin Oncol; 2015 Jul; 33(20):2296-302. PubMed ID: 26014296
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer.
Barnett JC; Alvarez Secord A; Cohn DE; Leath CA; Myers ER; Havrilesky LJ
Cancer; 2013 Oct; 119(20):3653-61. PubMed ID: 23921967
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer.
Shi Y; Chen J; Shi B; Liu A
Gynecol Oncol; 2022 Feb; 164(2):379-385. PubMed ID: 34920886
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab in treatment of high-risk ovarian cancer--a cost-effectiveness analysis.
Chan JK; Herzog TJ; Hu L; Monk BJ; Kiet T; Blansit K; Kapp DS; Yu X
Oncologist; 2014 May; 19(5):523-7. PubMed ID: 24721817
[TBL] [Abstract][Full Text] [Related]
17. Development of a platform for systemic antiangiogenesis therapy for advanced cervical cancer.
Tewari KS; Monk BJ
Clin Adv Hematol Oncol; 2014 Nov; 12(11):737-48. PubMed ID: 25674713
[TBL] [Abstract][Full Text] [Related]
18. The application of pharmacoeconomic modelling to estimate a value-based price for new cancer drugs.
Dranitsaris G; Truter I; Lubbe MS; Cottrell W; Spirovski B; Edwards J
J Eval Clin Pract; 2012 Apr; 18(2):343-51. PubMed ID: 21087368
[TBL] [Abstract][Full Text] [Related]
19. Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial.
Wysham WZ; Schaffer EM; Coles T; Roque DR; Wheeler SB; Kim KH
Gynecol Oncol; 2017 May; 145(2):340-345. PubMed ID: 28291545
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma.
Spencer SJ; Guzauskas GF; FeLizzi F; Launonen A; Dawson K; Veenstra DL; Masaquel A
J Manag Care Spec Pharm; 2021 May; 27(5):615-624. PubMed ID: 33586513
[No Abstract] [Full Text] [Related]
[Next] [New Search]